Recent studies have indicated that baseline circulating predictors from the host, including CD8+PD-1+ T cells, serum tumor markers, neutrophil to lymphocyte ratio (NLR), and diversity of gut microbiome, can aid in evaluating the therapeutic outcomes of ICI treatment (6–9). Here, PDCD1 is linked to neoplasm.